Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Mayo Clinic discovers ’new pathway’ against pancreatic cancer


Pancreatic cancer kills 30,000 Americans every year. Not only is there no cure, but there are no effective treatments. That may change if a new finding by Mayo Clinic researchers continues to show promise. In the March 15 issue of the journal Cancer Research, ( investigators describe discovering a key molecule that controls the growth, spread and survival of pancreatic cancer cells. This is a critical first step toward developing new and better treatments for patients with pancreatic cancer.

"This is a very exciting -- and surprising -- finding," says Daniel Billadeau, Ph.D., lead author of the report. To identify new target molecules with potentially therapeutic impact for a cancer for which there is currently no real useful treatment is incredibly important.

"Based on the literature, you would predict the opposite of what we found. But in fact, we determined that we can decrease a known regulator of cancer cell survival -- in effect, turn this regulator off -- and when we do, the pancreatic cancer cells undergo apoptosis (commit cell suicide) and die."

Significance of the Research

With this finding, a new path is cleared for researchers to target these key molecular players with new small molecule inhibitors to block their action, effectively turning off molecules that promote pancreatic cancer growth.

The finding may be applied to make pancreatic cells more sensitive to gemcitabine, the sole drug available for treating pancreatic cancer.

This discovery may lead to new drug development strategies for other cancers. Additional research will tell whether these same actors play a similar role in the spread of other cancer types.

The Key Finding

The Mayo Clinic researchers discovered a previously unrecognized role in pancreatic cancer for the GSK-3 Beta molecule. They determined that GSK-3 Beta is vital to pancreatic cancer cell survival and growth through its effects on a well-known gene regulator called NF Kappa B (pronounced "en-ef-kappa-bee").

The NF Kappa B protein is well known to researchers as a transcription factor that regulates many genes. In cancer cells, NF Kappa B regulates genes involved in cancer cell survival, proliferation and blood vessel formation (angiogenesis). NF Kappa B is hyperactive in many human cancers including pancreatic. The Mayo Clinic study shows that in pancreatic cancer, the activity of NF Kappa B is regulated by GSK-3 Beta. Researchers determined this by showing that if they could decrease GSK-3 Beta protein or inactivate it using small molecular inhibitors, they could likewise decrease NF Kappa B -- and deprive the pancreatic cancer cells of a means to grow and survive.

Notably, in pancreatic cancer, NF Kappa B activity is high -- which can cause resistance to chemotherapy drugs used to treat the disease. This new information suggests a potential means of treating pancreatic cancer by a two-pronged attack of administering the gemcitabine in combination with a drug to block GSK-3 Beta.

Nearly all die within five years of diagnosis

Despite recent advances in understanding how cancers work at the molecular level, pancreatic cancer lacks an effective treatment. Approximately 30,000 Americans are diagnosed with pancreatic cancer annually, and the disease kills the same number each year. Ninety percent of these cancers are pancreatic ductular adenocarcinoma, the fourth leading cause of cancer deaths in the United States. Pancreatic cancer patients have one of the poorest prognoses -- the five-year survival rate is 3 percent. Because pancreatic cancer is aggressive, spreads rapidly and few treatment options are available, researchers welcome any promising leads for improving diagnosis and therapy.

Bob Nellis | EurekAlert!
Further information:

More articles from Life Sciences:

nachricht Signaling Pathways to the Nucleus
19.03.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht In monogamous species, a compatible partner is more important than an ornamented one
19.03.2018 | Max-Planck-Institut für Ornithologie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

A new kind of quantum bits in two dimensions

19.03.2018 | Physics and Astronomy

Scientists have a new way to gauge the growth of nanowires

19.03.2018 | Materials Sciences

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Science & Research
Overview of more VideoLinks >>>